Adrien LEMAIGNEN

Adrien LEMAIGNEN

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of Infection
Verified
Journal Article
Open access
MGMarie Gousseff
Marie Gousseff
PPPauline Penot
Pauline Penot
LGLaure Gallay
Laure Gallay
DBDominique Batisse
Dominique Batisse
NBNicolas Benech
Nicolas Benech
EBElisabeth Botelho-Nevers
Elisabeth Botelho-Nevers
For the first 3 months of COVID-19 pandemic, COVID-19 was expected to be an immunizing non-relapsing disease. We report a national case series of 11 virologically-confirmed COVID-19 patients having experienced a second clinically- and virologically-confirmed acute COVID-19 episode. According to the clinical history, we discuss either re-infection or reactivation hypothesis. Larger studies including further virological, immunological and epidemiologic data are needed to understand the mechanisms of these recurrences.

1 February 2021 in Journal of Infection
Verified
Journal Article
Closed access
ALAdrien LEMAIGNEN
Adrien LEMAIGNEN
LBLouis Bernard
Louis Bernard
SMSimon Marmor
Simon Marmor
TFTristan Ferry
Tristan Ferry
LGLeslie Grammatico-Guillon
Leslie Grammatico-Guillon
PAPascal Astagneau
Pascal Astagneau

1 June 2020 in Medecine Et Maladies Infectieuses
Verified
Journal Article
Closed access
BAB. Aloy
B. Aloy
VLV. Launay-Vacher
V. Launay-Vacher
ABAlexandre Bleibtreu
Alexandre Bleibtreu
PBP. Bortolotti
P. Bortolotti
EFE. Faure
E. Faure
ALAdrien LEMAIGNEN
Adrien LEMAIGNEN

14 July 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
ALAdrien LEMAIGNEN
Adrien LEMAIGNEN
LBLouis Bernard
Louis Bernard
PTPierre Tattevin
Pierre Tattevin
JBJean-Pierre Bru
Jean-Pierre Bru
XDXavier Duval
Xavier Duval
ACAgnes Caille
Agnes Caille
Introduction Left-sided infective endocarditis (IE) is a serious infection with a heavy burden for patients and healthcare system. Oral switch after initial intravenous antibiotic therapy may reduce costs and improve patients’ discomfort without increasing unfavourable outcomes. We describe the methodology of two simultaneously conducted open-label randomised trials aiming to assess non-inferiority of oral switch as compared with entirely intravenous antibiotic therapy for the treatment of left-sided IE. Methods and analysis Two simultaneous multicentre open-label prospective randomised trials assessing non-inferiority of oral switch during antibiotic treatment as compared with entirely intravenous therapy in patients with left-sided IE are ongoing. One trial is dedicated to left-sided IE caused by multisusceptible staphylococci (Relais Oral Dans le traitement des Endocardites à staphylocoques ou streptOcoques (RODEO)-1) and the other is dedicated to left-sided IE caused by susceptible streptococci or enterococci (RODEO-2). It is planned to randomise 324 patients in each trial after an initial course of at least 10 days of intravenous antibiotic therapy either to continue intravenous antibiotic therapy or to switch to oral antibiotic therapy. The primary outcome is treatment failure within 3 months after the end of antibiotic treatment, a composite outcome defined by all-cause death and/or symptomatic embolic events and/or unplanned valvular surgery and/or microbiological relapse (with the primary pathogen). Secondary outcomes include patient quality of life, echocardiographic outcome, costs and efficiency associated with IE care. Statistical analysis will be performed with a non-inferiority margin of 10% and a one-sided 2.5% type I error. Ethics and dissemination Written informed consent will be obtained from all participants. This study was approved by Tours Research ethics committee (CPP TOURS-Region Centre-Ouest 1, 2015-R26, 23 February 2016). Study findings will be published in peer-reviewed journals and disseminated through presentation at relevant national and international conferences. Trial registration number EudraCT Number: 2015-002371-16 and NCT02701608; NCT02701595.

1 October 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
FTFlorent Von Tokarski
Florent Von Tokarski
ALAdrien LEMAIGNEN
Adrien LEMAIGNEN
APAntoine Portais
Antoine Portais
LFLaurent Fauchier
Laurent Fauchier
FHFanny Hennekinne
Fanny Hennekinne
LBLouis Bernard
Louis Bernard
The incidence of acute kidney injury (AKI) in infective endocarditis (IE), its risk factors and consequences on patient and renal survival remain debated. Patients hospitalized for a first episode of IE (possible or definite according to modified Duke criteria) between 2013 and 2016 were included. The primary endpoint was to determine risk factors for early AKI (E-AKI) during the first week of management of IE. A total of 276 patients were included: 220 (79.7%) had definite IE and 56 (20.3%) had possible IE. E-AKI occurred in 150 patients (53%). IE due to Staphylococcus aureus (OR 3.41; 95% CI 1.83-6.39; p<0.01), history of diabetes (OR 2.34; 95% CI 1.25-4.37; p<0.01), peripheral arterial disease (OR 2.59; 95% CI 1.07-6.23; p<0.05), immunological manifestations (OR 3.11; 95% CI 1.31-7.39; p=0.01), and use of norepinephrine (OR 3.44; 95% CI 1.72-7.02; p<0.01) were associated with E-AKI. In subgroup analysis, infectious disease consultation was associated with a lower risk of AKI at day 7 (OR 0.41; 95% CI 0.16-0.88; p=0.04). E-AKI was associated with 1-year mortality (OR 1.65; 95% CI 1.03-2.64; p=0.04) and chronic kidney disease progression (OR 2.23; 95% CI 1.30-3.82; p<0.01). E-AKI is common in IE and often associated with non-modifiable variables. Multidisciplinary management should be mandatory, and awareness of AKI diagnosis and etiological explorations should be raised.

8 December 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
OBOlivier Bahuaud
Olivier Bahuaud
CBCecile Le Brun
Cecile Le Brun
ALAdrien LEMAIGNEN
Adrien LEMAIGNEN
Tularemia, caused by the bacterium Francisella tularensis, is an infrequent zoonotic infection, well known in immunocompetent (but poorly described in immunocompromised) patients. Although there is no clear literature data about the specific characteristics of this disease in immunocompromised patients, clinical reports seem to describe a different presentation of tularemia in these patients. Moreover, atypical clinical presentations added to the fastidiousness of pathogen identification seem to be responsible for a delayed diagnosis, leading to a” loss of chance” for immunocompromised patients. In this article, we first provide an overview of the host immune responses to Francisella infections and discuss how immunosuppressive therapies or diseases can lead to a higher susceptibility to tularemia. Then, we describe the particular clinical patterns of tularemia in immunocompromised patients from the literature. We also provide hints of an alternative diagnostic strategy regarding these patients. In conclusion, tularemia should be considered in immunocompromised patients presenting pulmonary symptoms or unexplained fever. Molecular techniques on pathological tissues might improve diagnosis with faster results.